THALES
On 18 February, the Perseverance rover — a key component of the Mars 2020 mission — will touch down on the Red Planet after a long seven-month voyage. SuperCam , one of seven strategic onboard instruments, is a powerful combination of technologies designed to analyse, characterise and select Martian rock samples. SuperCam is the result of close collaboration between Los Alamos National Laboratory (LANL) in the United States and the astrophysics and planetology research institute in France (IRAP, CNRS / CNES / Université Toulouse III - Paul Sabatier), with contributions from the University of Hawaii and the University of Valladolid in Spain. The Mast Unit , the French part of SuperCam located at the top of the rover’s mast, was designed and built by a consortium of French laboratories1 from CNRS, universities and entities under the scientific lead of the IRAP team and under the responsibility of CNES, the French space agency. The laser supplied by Thales is a key part of the Mast Unit .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210215005423/en/
In 2012, Curiosity landed on Mars equipped with the first high-power laser to operate on the surface of another planet, a laser designed and developed by Thales for the ChemCam instrument. The ChemCam laser has been operating faultlessly for over eight years and has fired close to 855,000 shots to date as Curiosity has made its 24-kilometre trek across the surface of the Red Planet. Data from ChemCam has already helped to prove that conditions on Mars were once suitable for microbial life.
The SuperCam instrument, a new and more powerful version of ChemCam, is designed to take Mars exploration to a new level. Like ChemCam, the SuperCam laser will use an infrared beam to heat material to a temperature of around 10,000°C and vaporise it — a method called laser induced breakdown spectroscopy. Coupled with a special camera, this makes it possible to determine the chemical composition of Martian rock samples by measuring the colours of light in the plasma created.
Unlike ChemCam, however, the SuperCam laser can also emit a green laser beam, which will help determine the molecular composition of surface materials. This green beam excites the chemical bonds in samples and produces a different signal according to their various linked components. This analysis technique, known as Raman spectroscopy, will be tested for the first time on Mars and will enable scientists to detect any markers of life. The green laser will also be used to induce fluorescence in mineral and organic compounds, allowing scientists to determine their constituent components with greater accuracy.
“We’re proud to have provided NASA with the first two lasers to operate on Mars. The Mars 2020 mission is a decisive step forward in the study of the Red Planet and preparations for future expeditions. SuperCam, the ‘eyes’ of Perseverance, is the result of close collaboration between partners across the international scientific community. Thales's SuperCam laser delivers unrivalled performance and will enable Perseverance to perform its exploration mission throughout its time on the surface of Mars.” Christophe Salomon, Executive Vice President, Land and Air Systems
About Mars 2020
The goal of the Mars 2020 mission is to study the Red Planet’s surface, search for signs of past life, take rock and dust samples at selected sites and store them for retrieval by the future Mars Sample Return (MSR) mission, which will be conducted jointly with the European Space Agency. Thales Alenia Space is closely involved in the MSR mission.
The Mars 2020 mission is designed to gather the necessary knowledge and test the technologies that will be vital for future human expeditions to the Red Planet.
How to produce oxygen from the Martian atmosphere? What resources are available? Is there water beneath the surface, for example? How to improve landing techniques and characterise weather conditions, dust levels and other environmental conditions that could affect the life and work of future astronauts on Mars? These are just some of the questions the Perseverance mission will seek to answer.
About Thales lasers
For more than 35 years, Thales has been a world leader in design, development and manufacturing of high energy nanosecond lasers for industrial applications and the most powerful ultra-short Ti:Sa femtosecond laser systems for leading scientific applications with peak power up to 10 petawatts.
Thales provides the most reliable and easy-to-use products, a unique combination of technological expertise and robustness for implementation into industrial applications that require highest availability such as laser annealing, laser lift-off, laser shock peening and cutting of composites for various industries such as aerospace, microelectronics, flat panel displays and many others. Thales provides also a full range of services, which are optimized to support each customer.
About Thales Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months). Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments. |
PLEASE VISIT
[1] The Irap ; the Laboratoire d’études spatiales et d’instrumentation en astrophysique (LESIA, Observatoire de Paris-PSL/CNRS/SU/Université de Paris) ; the Laboratoire d’astrophysique de Bordeaux (LAB, CNRS/Université de Bordeaux) ; the Laboratoire « atmosphères et observations spatiales » (LATMOS, CNRS/SU/UVSQ) ; l’Observatoire Midi-Pyrénées (OMP, CNRS/IRD/Météo-France/Université de Toulouse III – Paul Sabatier) ; the Institut d’astrophysique spatiale (IAS, CNRS/Université Paris-Saclay).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210215005423/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom